In the phase 3 CheckMate 914 trial, Adjuvant #nivolumab plus #ipilimumab failed to improve the clinical outcomes in patients with localised clear cell #renal cell carcinoma (#RCC) who were at high risk of relapse after radical or partial nephrectomy.

In this randomized trial, 816 patients were randomly assigned to receive either adjuvant nivolumab plus ipilimumab (405 patients) or placebo (411 patients). The median disease-free survival was not reached in the nivolumab plus ipilimumab group and was 50·7 months in the placebo group (HR= 0·92; p=0·53).